Related Experiment Videos
Does brain 3,4-dihydroxyphenylacetic acid reflect dopamine release?
The Journal of Pharmacy and Pharmacology
|February 1, 1987
Summary
Sulpiride increases dopamine and its metabolites DOPAC and HVA in rat striatum. Benztropine did not affect sulpiride-induced dopamine or DOPAC, but lowered HVA, suggesting dopamine deamination may occur before release.
Area of Science:
- Neuropharmacology
- Dopamine Metabolism
Background:
- Sulpiride is a dopamine antagonist.
- Benztropine is an anticholinergic agent.
- Dopamine metabolism involves deamination and other pathways.
Purpose of the Study:
- To investigate the effect of benztropine on sulpiride-induced changes in dopamine and its metabolites.
- To explore the timing of dopamine deamination relative to its release.
Main Methods:
- Rats were administered sulpiride (75 mg/kg) or a combination of benztropine (25 mg/kg) and sulpiride.
- Striatal levels of dopamine, DOPAC, and HVA were measured.
Main Results:
- Sulpiride administration significantly increased striatal dopamine, DOPAC, and HVA.
- Benztropine did not attenuate the sulpiride-induced increase in dopamine or DOPAC.
- Benztropine co-administration significantly reduced HVA levels compared to sulpiride alone.
Conclusions:
- Dopamine deamination can occur prior to release under certain conditions, such as with sulpiride administration.
- Benztropine's effect on HVA suggests an interaction with dopamine metabolic pathways.